세계의 조진균증 치료 시장 보고서 : 질환 유형별, 치료 유형별, 약제 클래스별, 유통 채널별, 지역별(2025-2033년)

The global onychomycosis treatment market size reached USD 3.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.5% during 2025-2033. The rising prevalence of this fungal infection among adults and millennials due to the increased exposure to public swimming pools and the use of tight, contaminated, or soiled clothes, shoes, socks, etc., is primarily driving the market.

Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can lead to discomfort, chronic pain and disfigurement. Proximal subungual, white superficial and distal subungual are some of the types of onychomycosis. It is a common nail infection in patients with athlete's foot and is caused by various organisms, such as dermatophytes, yeasts and non-dermatophyte molds. Onychomycosis is characterized by symptoms, including distortion in the shape of nails, foul smell, whitish to yellow-brown discoloration and brittle, ragged and crumbly texture of the nails. It is usually diagnosed through potassium, oxygen and hydrogen (KOH) examination, culture and histopathological examinations of nail clippings and nail biopsies and is treated through laser therapy, drugs and photodynamic therapies.

Onychomycosis Treatment Market Trends:

The increasing prevalence of chronic medical ailments, such as onychomycosis, human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is highly prone to circulatory disorders and weakened immune system, is providing a thrust to the market growth. Onychomycosis is also highly prevalent among millennials and adults due to the increased exposure to public swimming pools and utilization of tight, contaminated or soiled clothes, shoes and socks. Additionally, the development of water-soluble antifungal treatment solutions that can be administered orally is providing a thrust to the market growth. They aid in preventing secondary bacterial infections and prevent the growth of fungus. Other factors, including the widespread utilization of topical nail lacquers and ointments to maintain nail hygiene, along with the significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Disease Type:

• Distal Subungual Onychomycosis
• Proximal Subungual Onychomycosis
• White Superficial Onychomycosis
• Candidal Onychomycosis
• Others

Breakup by Treatment Type:

• Laser Therapy
• Photodynamic Therapy
• Drug Treatment

Breakup by Drug Class:

• Allylamine
• Azole
• Griseofulvin
• Others

Breakup by Distribution Channel:

• Hospitals and Clinics
• Online Stores
• Retail Pharmacies
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories, Galderma SA, GlaxoSmithKline PLC, Kaken Pharmaceutical Co. Ltd, Lumenis Ltd, Moberg Pharma AB, Novartis AG, Pfizer Inc. and The OTC Lab B.V.

Key Questions Answered in This Report

• 1.What was the size of the global onychomycosis treatment market in 2024?
• 2.What is the expected growth rate of the global onychomycosis treatment market during 2025-2033?
• 3.What are the key factors driving the global onychomycosis treatment market?
• 4.What has been the impact of COVID-19 on the global onychomycosis treatment market?
• 5.What is the breakup of the global onychomycosis treatment market based on the disease type?
• 6.What is the breakup of the global onychomycosis treatment market based on the treatment type?
• 7.What is the breakup of the global onychomycosis treatment market based on the distribution channel?
• 8.What are the key regions in the global onychomycosis treatment market?
• 9.Who are the key players/companies in the global onychomycosis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Onychomycosis Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Disease Type

• 6.1 Distal Subungual Onychomycosis
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Proximal Subungual Onychomycosis
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 White Superficial Onychomycosis
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Candidal Onychomycosis
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Treatment Type

• 7.1 Laser Therapy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Photodynamic Therapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Drug Treatment
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Drug Class

• 8.1 Allylamine
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Azole
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Griseofulvin
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Online Stores
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Retail Pharmacies
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bausch Health Companies Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Cipla Limited
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Dr. Reddy's Laboratories
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Galderma SA
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 GlaxoSmithKline PLC
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Kaken Pharmaceutical Co. Ltd
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Lumenis Ltd
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 SWOT Analysis
  • 15.3.8 Moberg Pharma AB
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
  • 15.3.9 Novartis AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Pfizer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 The OTC Lab B.V.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio